CS Paper Radar

El Agente Fármaco: A Scalable AI Scientist for Drug Discovery

Marcel Müller, Mohammad Ghazi Vakili, Yoshihiro Ogura, Ella Ashoori, Shimeng Wang, Alessandro S. Nascimento, Eddie Calleja, Yutong Zhao, Yimeng Liu, Ella Miray Rajaonson, Aiwei Yin, Jiaru Bai, Yunheng Zou, Abraham C. Stern, Varinia Bernales, Alán Aspuru-Guzik

cs.AI cs.MAq-bio.BM ·submitted 2026-11-02 19:08 UTC · v1
benchmark

Abstract

Computational drug discovery offers a growing range of tools for proposing and evaluating molecules, but combining them and deciding what to do next still requires substantial expert effort. Here, we introduce El Agente Fármaco, an AI scientist that uses modern large language model (LLM) technology to turn discovery goals expressed in everyday language into complex, scalable computational screening workflows. The agentic harness selects scientific tools, reviews their results, and adjusts subsequent steps to the target and the user's objectives. Our approach centers on a shared scientific memory: Fármaco Atlas, which stores molecules, structures, and results together with their provenance -- a record of how they were obtained. The agent uses targeted database queries to retrieve the evidence needed for each decision. A single request can launch calculations for an entire collection of molecules, without requiring a separate LLM decision for every compound. This design limits the information the model must process as screening collections grow, while keeping the underlying results available for inspection and further analysis. The integrated tools support molecule generation, prediction of binding and molecular properties, and searches for compounds available for purchase. In a retrospective comparison with an expert-led campaign, the agent proposed chemically distinct candidates with competitive docking scores and higher calculated drug-likeness under explicitly imposed selection criteria. In a 22-task benchmark against plain tool calls and Codex, the agent achieved the highest observed mean model-judged score, with lower median cumulative token use and peak context. Fármaco provides a foundation for flexible, scalable drug discovery workflows that connect scientific reasoning with an enduring, traceable record of computational work.

Comment
63 pages, 13 figures, including Supporting Information

Closest papers

Nearest neighbours by meaning across the whole index.

DrugCoding: A Scientific Programming Agent for Drug Discovery

cs.AI cs.MA ·2026-11-10 ·Junwei Hu, Zhuohao Lin, Kun Li, Hengnan Zhang
benchmark similarity 0.79
Abstract

Drug discovery involves multiple interconnected research stages, including molecular design, property prediction, and virtual screening. These processes are characterized by complex workflows, interdependent computational tasks, and diverse specialized tools, placing substantial demands on the coordination of scientific models and computational resources. However, existing large language model (LLM)-based scientific agents still face challenges in autonomous planning of complex tasks, adaptive selection of specialized models, and reliable execution of multi-stage scientific computations, limiting their effectiveness in automating complex drug discovery workflows. To address these challenges, we propose DrugCoding, a scientific programming agent system that integrates scientific task planning, adaptive model routing, multi-agent collaboration, and programmatic tool execution. DrugCoding enables autonomous task planning and dynamic model adaptation for complex research objectives. It can flexibly invoke specialized scientific models, autonomously generate and execute code according to task requirements, and leverage multi-agent collaboration to support efficient execution and reliable validation of complex scientific tasks. To evaluate DrugCoding's performance in scientific tool invocation and multi-stage task execution, we conduct multi-turn tool-calling experiments across diverse language models and scientific tool interfaces. Experimental results demonstrate that DrugCoding achieves an average session-level Pass@1 of 97.35% on the full benchmark, outperforming the strongest baseline, Codex, by 9.24%. On the challenging subset, DrugCoding achieves 97.92%, exceeding the strongest baseline.

0.14

MADDIE: Multi-Agent Drug Discovery Engine

cs.AI ·2026-10-12 ·Ye Liu, Reza Averly, Avery Meyer, Frazier N. Baker, Ruoxi Gao +2 more
code/data similarity 0.79
Abstract

Drug discovery remains a resource-intensive and time-consuming process, involving billions of dollars and a decade of development to advance a drug to market. While many in silico tools have accelerated this process, operating them still demands substantial time, effort, and expertise from medicinal chemists. Autonomous systems built on Large Language Models (LLMs) have emerged as a promising solution, yet current designs limit their performance. Existing single-agent systems scale poorly to long-horizon, multi-step, and realistic tasks, whereas multi-agent systems typically execute predefined workflows that cannot capture the iterative, non-linear nature of a real drug discovery campaign. Here, we present MADDIE, a multi-agent drug discovery engine. It comprises a central agent, Orchestrator, and four specialized worker agents: HitIdentifier, LeadOptimizer, Synthesizer, and Evaluator, each representing a critical step in a drug discovery campaign. Under Orchestrator's orchestration and coordination, these worker agents are composed into flexible workflows, enabling MADDIE to adapt its strategy and navigate the drug discovery pipeline end-to-end. Across 50 protein targets, MADDIE produces molecules satisfying key property requirements and their synthesis routes, outperforming existing agentic systems, generative models, and general-purpose LLMs by a wide margin. Our analysis reveals how these agents collaborate and that MADDIE can employ different strategies across targets to achieve the campaign's goal, while still being efficient in time and tokens. Together, they demonstrate MADDIE as a low-cost, effective, and efficient autonomous engine for accelerating drug discovery. Code and dataset is available via https://github.com/ninglab/MADDIE.

0.49

Toward a Locally Deployable Agentic Co-Scientist: Small-Model Planning for Early-Stage Drug Discovery

cs.AI ·2026-10-03 ·Tian Liang, Jiayu Chang, Alejandro F. Frangi, Mobarak I. Hoque, Richard A. Bryce
published similarity 0.76
Abstract · 22 pages, 4 figures. Accepted at the AI for Drug Discovery Workshop, NeurIPS 2026

Early-stage computational drug discovery requires coordinating heterogeneous scientific tools across multi-step workflows. We present a lightweight, tool-augmented framework in which a locally deployable compact language model plans calls to 18 modular tools. A Unified Molecular Schema maintains shared molecular records, while a plug-in interface supports tool replacement and extension. We construct 1,263 manually refined query-plan pairs through workflow-graph path coverage and apply LoRA fine-tuning to three compact model families. Under the query-level split, all fine-tuned models generate fully parseable and schema-compliant plans on 47 held-out cross-group queries. Llama 3.2-3B achieves a tool-selection F1 of 0.998, sequence exact match of 0.979, and argument F1 of 0.960. Under the stricter workflow-grouped split, which excludes identical ordered tool sequences across partitions, sequence exact match reaches 0.452 to 0.548, highlighting the remaining difficulty for compact models in generating complete workflow paths unseen during training. These results demonstrate the feasibility of compact, locally deployable planning while identifying compositional generalization as an important direction for further improvement.

0.33

M3OS: A Monte Carlo Graph Search-Orchestrated Multi-Agent LLM System for Evidence-Traced Molecular Optimization

cs.LG q-bio.BM ·2026-09-28 ·Junjie Wang, Yaowei Jin, Ruohui Tang, Guonan Cui, Haojie Wang +5 more
similarity 0.75
Abstract

Small-molecule optimization integrates medicinal-chemistry reasoning and computational evidence through iterative, multi-objective decisions. When large language models (LLMs) reason over optimization histories stored primarily in conversational context, they must recover candidate identities, prior evaluations, and task constraints to guide subsequent decisions. We present M3OS, a multi-agent LLM system that decouples molecular-design reasoning from optimization-state management through Monte Carlo graph search. A persistent graph links evaluated candidates, parent-child transformations and evaluation evidence, while rewards and visit statistics guide LLM-assisted parent selection. Two branches combine tool-driven candidate generation with knowledge- and case-guided medicinal-chemistry editing. An execution harness controls graph updates through structured output extraction, molecular validation and task-bound evaluation. Agents receive role-specific contexts, while the graph preserves optimization trajectories beyond their active contexts. Across three molecular optimization benchmarks, M3OS achieves higher success rates than baselines, supporting the integration of persistent search state, specialized agents and controlled execution for multi-constraint optimization.

0.21

MoLRSI: A Recursive Self-Improving AI agent for Molecular Discovery

cs.AI ·2026-10-29 ·Yikun Zhang, Xiwei Cheng, Mingze Yuan, Yu Zhang, Brian Shim +13 more
community pick similarity 0.74
Abstract · v2: updated the author list

Molecular discovery requires navigating vast combinatorial search spaces while balancing competing biological objectives. AI agents can automate expert-defined molecular design protocols, but automation alone does not address how to optimize workflows for new tasks or improve their development through experience. Here we introduce MoLRSI, an AI agent that combines systematic optimization of workflows and model architectures with persistent cross-task memory to recursively improve its search policy for molecular discovery. Workflow performance, refinement outcomes, and execution feedback guide subsequent searches, allowing the agent to improve both its workflows and its strategy for developing them. We evaluate MoLRSI in two challenging molecular discovery settings that require balancing competing properties. In antibiotic discovery, MoLRSI developed a screening workflow balancing antibacterial activity, cytotoxicity and structural novelty, achieving an experimental hit rate of 15.9%, compared with 8.7% for a previous expert-led workflow using the same training data and screening library. In de novo peptide-MHC binder design, MoLRSI developed workflows that jointly consider target binding and specificity, producing eight experimentally validated hits against MART-1 and SARS-CoV-1 pMHCs with preferential binding over tested off-targets while Claude Science completely failed. These findings demonstrate how experience-guided workflow optimization can address competing discovery objectives while improving the search strategies used in subsequent campaigns.

0.39

ReproBAIT: Can coding agents build their own biological AI tools?

cs.AI cs.CYcs.LG ·2026-10-14 ·Shiv Muthupandiyan, Tolga H. Dur, Mac Walker, Timo Flesch, Mahmoud Ghanem +6 more
code/data similarity 0.73
Abstract

Large language models are increasingly competent at leveraging scientific knowledge and existing computational tools to execute complex workflows. At present, little information exists on their ability to reconstruct tools when given limited descriptions of such tools. We introduce an evaluation titled ReproBAIT (Reproducing Biological AI Tools), which measures the ability of coding agents to design, implement, and train biological AI tools taken from published research across a range of information access conditions. The coding agent is securely sandboxed without internet access and receives training data, a fixed time and compute budget, and limited information about the tool to replicate. We then score the reproduced biological AI tool based on its performance (tool-specific metrics) on held-out data. We evaluated a set of biological AI tools of varying complexities: ProteinMPNN, an inverse protein folding tool, RFdiffusion3, an all-atom generative diffusion tool, and a closed-source molecular design tool. We institute a methodology to check for memorisation, as the open source tools are likely to be included in models' pretraining corpus. Across a range of leading closed- and open-source coding agents, we find substantial reproduction capability for some selected tools, though limited capability for a highly complex tool. We find moderate evidence consistent with memorisation, varying across coding agents. These results suggest that tool developers need to be increasingly cautious when releasing information about the tools publicly; re-creation of the tool based on such information could undermine a tool's commercial value or invalidate dual-use managed access strategies.

0.47

Magnolia: A Persistent-Memory Agent Framework for Computational Chemistry

cs.AI q-bio.BM ·2026-10-19 ·Tao Jiang, Benjamin Navet, Yousouf Taghzouti, Fabien Gandon, Louis-Félix Nothias +1 more
code/data similarity 0.73
Abstract · https://github.com/HolobiomicsLab/Magnolia-AI

Chemistry has recently entered a high-data regime as molecular databases from high-throughput platforms or computational studies have become available. Increasing automation within the chemical sciences leads to a more digital and precision chemistry. Dedicated scientific agents are becoming central to guiding the chemist through an ever-increasing amount of data and findings, including negative ones. Here, we introduce Magnolia, a persistent-memory artificial intelligence agent framework that integrates computational protocols, from docking to quantum chemistry, lab notebooks and chat logs relying on large language models (LLMs). It relies on a three-tier memory system: session-level observations are automatically captured and distilled into structured learnings, confirmed and elevated to project-tier entries and, when human-validated, promoted to cross-project rules that actively guide subsequent work and provide direct chemical feedback. We illustrate Magnolia on four case studies: quantum-chemical evaluation of aromatic systems (COMPAS database), molecular dynamics of butane and of modified DNA, and a protein-peptide docking campaign. Across these projects, Magnolia tracked 317 runs and accumulated 116 project-tier entries, from which four cross-project rules were promoted; in controlled replays of four tasks, runs with memory passed the checks that runs without it failed (for example, ten of ten docking-configuration checks, against one to four of ten). By combining automation, reproducibility, and human-in-the-loop control, our Magnolia framework streamlines docking, molecular dynamics and quantum chemistry calculations with direct analysis and LLM-augmented feedback, offering accelerated access to computational (bio)chemistry.

0.24

Designing a Robust LLM-Based Evaluation System for Agentic AI in Drug Discovery Through Human Alignment

cs.LG ·2026-08-21 ·Emma Granqvist, Rocío Mercado, Samuel Genheden
similarity 0.73
Abstract

Agentic large language model (LLM) systems are reshaping scientific workflows in chemistry and drug discovery, but evaluating their open-ended, tool-augmented outputs remains a fundamental bottleneck. The LLM-as-a-Judge paradigm has emerged as a scalable alternative, but existing drug discovery benchmarks deploy LLM judges without validating their alignment with human experts. In this work, we present an LLM-as-a-Judge evaluation framework for ChatInvent, an agentic drug discovery assistant deployed at AstraZeneca, with five contributions. First, we define four output-quality evaluation dimensions---Completeness, Relevancy, Structural Clarity, and Scope Adherence---alongside deterministic Tool Call Correctness checks. Second, we validate the judge through a human alignment study with five expert annotators, comparing Gemini 3.1 Pro, Claude Opus 4.7, GPT-5, and Llama 3.1 70B as candidate judges. Third, we optimize the best-performing judge using few-shot demonstrations of human-annotated examples, improving alignment with the human majority vote from 0.80 to 0.86. Fourth, applying the optimized judge to 70 held-out questions, we surface concrete limitations and find no strong evidence that informal phrasing degrades output quality; it may, however, still be helpful to have the LLM rewrite the original question before querying the agent. Finally, we extend the framework to 38 adversarial questions that are ambiguous, invalid, out-of-scope or ethically sensitive, and show that the agent's refusal behavior is guided by the stated intent of a request. Our framework provides a reusable template for human-aligned evaluation of agentic systems in scientific domains.

0.24